echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Protollin U.S. Phase 1 clinical study completed the first patient administration

    Protollin U.S. Phase 1 clinical study completed the first patient administration

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 8, Tianjing Bio announced that the US Phase 1 clinical study of the new drug Protollin for the treatment of Alzheimer's disease has completed the first patient administration


    Today, there are approximately tens of millions of Alzheimer's patients worldwide and there is no effective cure


    According to the previous cooperation agreement, Tianjing Biotechnology and Jiangsu Enhua Pharmaceutical obtained the global development, production and commercialization of Protollin from the Brigham Hospital affiliated to Harvard Medical School and Inspirevax (formerly known as "Biodextris")


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.